Intuitive Surgical, Inc. (ISRG) EBITDA Margin: 35.99%
Is Intuitive Surgical, Inc.’s EBITDA margin high or low?
Intuitive Surgical, Inc.'s EBITDA margin of 35.99% is in line with its 5-year average of 33.18%, near the high end of its 5-year range (30.42%–37.32%).
The EBITDA margin for Intuitive Surgical, Inc. (ISRG) is 35.99% as of Tuesday, June 9, 2026. It is above its 12-month average by 3.35% (34.83%).
ISRG EBITDA Margin Chart
ISRG Average EBITDA Margin Chart
ISRG Current vs Average EBITDA Margin Chart
ISRG EBITDA Margin Metrics
EBITDA MARGIN
35.99%
EBITDA MARGIN AVG TTM
34.83%
EBITDA MARGIN AVG 3Y
32.83%
EBITDA MARGIN AVG 5Y
33.18%
EBITDA MARGIN AVG 10Y
34.59%
EBITDA MARGIN AVG 15Y
36.10%
EBITDA MARGIN AVG 20Y
36.34%
CURRENT VS TTM AVG
+3.35%
CURRENT VS 3Y AVG
+9.62%
CURRENT VS 5Y AVG
+8.47%
CURRENT VS 10Y AVG
+4.06%
CURRENT VS 15Y AVG
-0.30%
CURRENT VS 20Y AVG
-0.97%
ISRG Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intuitive Surgical, Inc. (ISRG) | — | 35.99% | 34.83% | 32.83% | 33.18% |
| Pfizer Inc. (PFE) | $146.48B | 24.12% | 26.30% | 27.39% | 29.84% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 46.12% | 30.77% | 33.17% | 31.82% |
| Abbott Laboratories (ABT) | $158.94B | 26.06% | 25.95% | 26.39% | 26.63% |
| Danaher Corporation (DHR) | $133.37B | 28.27% | 29.38% | 31.44% | 31.51% |
| CVS Health Corporation (CVS) | $123.84B | 2.45% | 3.06% | 3.76% | 4.57% |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 25.73% | 26.63% | 26.49% | 27.97% |
| Amgen Inc. (AMGN) | $185.96B | 43.12% | 41.54% | 45.45% | 46.07% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 30.18% | 18.37% | 30.35% | 29.39% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 41.14% | 22.77% | 35.47% | 38.89% |
Margin Comparison
Gross Margin
66.0%
EBITDA Margin
36.0%
Operating Margin
29.3%
Net Margin
28.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Intuitive Surgical, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Intuitive Surgical, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The EBITDA margin for ISRG stock is 35.99%.
- Is Intuitive Surgical, Inc.'s EBITDA margin high or low?
- Intuitive Surgical, Inc.'s EBITDA margin of 35.99% is in line with its 5-year average of 33.18%, near the high end of its 5-year range (30.42%–37.32%).
- What is the TTM average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The TTM average EBITDA margin for ISRG stock is 34.83%.
- What is the 3Y average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The 3Y average EBITDA margin for ISRG stock is 32.83%.
- What is the 5Y average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The 5Y average EBITDA margin for ISRG stock is 33.18%.
- What is the 10Y average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The 10Y average EBITDA margin for ISRG stock is 34.59%.
- What is the 15Y average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The 15Y average EBITDA margin for ISRG stock is 36.10%.
- What is the 20Y average EBITDA margin for Intuitive Surgical, Inc. (ISRG)?
- The 20Y average EBITDA margin for ISRG stock is 36.34%.
Intuitive Surgical, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 35.99% |
| 2024-12-31 | 33.66% |
| 2023-12-31 | 30.45% |
| 2022-12-31 | 31.23% |
| 2021-12-31 | 37.32% |
| 2020-12-31 | 30.42% |
| 2019-12-31 | 35.22% |
| 2018-12-31 | 35.50% |
| 2017-12-31 | 37.01% |
| 2016-12-31 | 38.85% |
| 2015-12-31 | 34.79% |
| 2014-12-31 | 29.24% |
| 2013-12-31 | 40.61% |
| 2012-12-31 | 42.95% |
| 2011-12-31 | 42.18% |
| 2010-12-31 | 42.15% |
| 2009-12-31 | 39.16% |
| 2008-12-31 | 38.39% |
| 2007-12-31 | 36.58% |
| 2006-12-31 | 38.27% |
| 2005-12-31 | 33.21% |
| 2004-12-31 | 20.39% |
| 2003-12-31 | -1.36% |
| 2002-12-31 | -21.76% |
| 2001-12-31 | -30.33% |
| 2000-12-31 | -65.82% |
| 1999-12-31 | -169.80% |
Related Metrics
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- David J. Rosa